NATCO receives approval for the drug for the treatment of Covid-19 in India

Natco Pharma Limited {NSE: NATCOPHARM; BSE: 524816) has received approval for Covid 19 drug Molnupiravir Capsules 200 mg. for Indian market, which will be sold under brand name MOLNUNAT®. Molnupiravir is the first Covid drug authorized by Drugs Controller General {India) (DCGI) for the treatment of Covid 19 infection with Sp02>93% and who have high risk of progression of the disease including hospitalization or death. This capsule was earlier approved in United Kingdom and United States of America.

MOLNUNAT will be marketed by Natco and will be priced affordably. Molnupiravir is the first Covid drug available in Indian market with a minimal dosage duration of 5 days with promising viral clearance. Phase 3 trials of Molnupiravir has shown significant reduction in hospitalization of Covid 19 patients.

MOLNUNAT is expected to be launched this week by Natco in the Indian market.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 890.45 as compared to the previous close of Rs. 889.55. The total number of shares traded during the day was 7318 in over 715 trades.

The stock hit an intraday high of Rs. 894.65 and intraday low of 882.55. The net turnover during the day was Rs. 6492583.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 NATCOPHARM Molnupiravir Approval Covid19Treatment